<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Transplant</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Transplant</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1600-6143</journal-id><journal-id journal-id-type="publisher-id">AJT</journal-id><journal-title-group><journal-title>American Journal of Transplantation</journal-title></journal-title-group><issn pub-type="ppub">1600-6135</issn><issn pub-type="epub">1600-6143</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7436557</article-id><article-id pub-id-type="doi">10.1111/ajt.16250</article-id><article-id pub-id-type="publisher-id">AJT16250</article-id><article-categories><subj-group subj-group-type="overline"><subject>Minireview</subject></subj-group><subj-group subj-group-type="heading"><subject>Minireviews</subject></subj-group></article-categories><title-group><article-title>Cyclosporine and COVID&#x02010;19: Risk or Favorable?</article-title></title-group><contrib-group><contrib id="ajt16250-cr-0001" contrib-type="author"><name><surname>Poulsen</surname><given-names>Nadia Nicholine</given-names></name><xref ref-type="aff" rid="ajt16250-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ajt16250-cr-0002" contrib-type="author"><name><surname>von Brunn</surname><given-names>Albrecht</given-names></name><xref ref-type="aff" rid="ajt16250-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ajt16250-cr-0003" contrib-type="author"><name><surname>Hornum</surname><given-names>Mads</given-names></name><xref ref-type="aff" rid="ajt16250-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="ajt16250-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ajt16250-cr-0004" contrib-type="author" corresp="yes"><name><surname>Blomberg Jensen</surname><given-names>Martin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3800-4253</contrib-id><xref ref-type="aff" rid="ajt16250-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ajt16250-aff-0005">
<sup>5</sup>
</xref><address><email>blombergjensen@gmail.com</email></address></contrib></contrib-group><aff id="ajt16250-aff-0001">
<label><sup>1</sup></label>
<institution>Group of Skeletal, Mineral, and Gonadal Endocrinology</institution>
<institution>Department of Growth and Reproduction, Rigshospitalet</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff><aff id="ajt16250-aff-0002">
<label><sup>2</sup></label>
<institution>Max von Pettenkofer&#x02010;Institute</institution>
<institution>Ludwig&#x02010;Maximilians&#x02010;University Munich</institution>
<named-content content-type="organisation-division">German Center for Infection Research (DZIF)</named-content>
<named-content content-type="street">Partner Site Munich</named-content>
<postal-code>80336</postal-code>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ajt16250-aff-0003">
<label><sup>3</sup></label>
<institution>Department of Nephrology, Rigshospitalet</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff><aff id="ajt16250-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Clinical Medicine</named-content>
<named-content content-type="organisation-division">Faculty of Health and Medical Sciences</named-content>
<institution>University of Copenhagen</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff><aff id="ajt16250-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Division of Bone and Mineral Research</named-content>
<institution>HSDM/HMS Harvard University</institution>
<city>Boston</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Corresponding author<break/>
Martin Blomberg Jensen<break/>
Email: <email>blombergjensen@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>8</month><year>2020</year></pub-date><elocation-id>10.1111/ajt.16250</elocation-id><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 The American Society of Transplantation and the American Society of Transplant Surgeons <copyright-statement>--><copyright-statement content-type="article-copyright">This article is protected by copyright. All rights reserved.</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:AJT-9999-na.pdf"/><abstract id="ajt16250-abs-0001"><title>Abstract</title><p>The coronavirus disease 2019 (COVID&#x02010;19) pandemic is declared a global health emergency. COVID&#x02010;19 is triggered by a novel coronavirus: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS&#x02010;CoV2). Baseline characteristics of admitted patients with COVID&#x02010;19 show that adiposity, diabetes and hypertension are risk factors for developing severe disease, but so far immunosuppressed patients that are listed as high&#x02010;risk patients have not been more susceptible to severe COVID&#x02010;19 than the rest of the population. Multiple clinical trials are currently being conducted, which hopefully can identify more drugs that can lower mortality, morbidity and burden on the society. Several independent studies have convincingly shown that cyclosporine inhibit replication of several different coronaviruses <italic>in vitro</italic>. The cyclosporine&#x02010;analog Alisporivir has recently been shown to inhibit SARS&#x02010;CoV2 <italic>in vitro</italic>. These findings are intriguing, although there is no clinical evidence for a protective effect to reduce the likelihood of severe COVID&#x02010;19 or to treat the immune storm or adult respiratory distress syndrome (ARDS) that often causes severe morbidity. Here, we review the putative link between COVID&#x02010;19 and cyclosporine, while we await more robust clinical data.</p></abstract><counts><fig-count count="0"/><table-count count="0"/><page-count count="21"/><word-count count="392"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>accepted-manuscript</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.7 mode:remove_FC converted:19.08.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="ajt16250-ntgp-0001"><fn id="ajt16250-note-0001"><p>This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/ajt.16250</p></fn></fn-group></notes></front></article>